SYRE
Price
$22.64
Change
-$0.79 (-3.37%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.82B
105 days until earnings call
Intraday BUY SELL Signals
WVE
Price
$6.66
Change
-$0.29 (-4.17%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.16B
117 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SYRE vs WVE

Header iconSYRE vs WVE Comparison
Open Charts SYRE vs WVEBanner chart's image
Spyre Therapeutics
Price$22.64
Change-$0.79 (-3.37%)
Volume$15.57K
Capitalization1.82B
Wave Life Sciences
Price$6.66
Change-$0.29 (-4.17%)
Volume$80.03K
Capitalization1.16B
SYRE vs WVE Comparison Chart in %
SYRE
Daily Signal:
Gain/Loss:
WVE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
SYRE vs. WVE commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Buy and WVE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (SYRE: $23.43 vs. WVE: $6.95)
Brand notoriety: SYRE and WVE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 64% vs. WVE: 97%
Market capitalization -- SYRE: $1.82B vs. WVE: $1.16B
SYRE [@Biotechnology] is valued at $1.82B. WVE’s [@Biotechnology] market capitalization is $1.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green whileWVE’s FA Score has 0 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • WVE’s FA Score: 0 green, 5 red.
According to our system of comparison, WVE is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 5 TA indicator(s) are bullish while WVE’s TA Score has 4 bullish TA indicator(s).

  • SYRE’s TA Score: 5 bullish, 5 bearish.
  • WVE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than WVE.

Price Growth

SYRE (@Biotechnology) experienced а +2.54% price change this week, while WVE (@Biotechnology) price change was -13.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

SYRE is expected to report earnings on Feb 26, 2026.

WVE is expected to report earnings on Mar 10, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.82B) has a higher market cap than WVE($1.16B). SYRE YTD gains are higher at: 0.644 vs. WVE (-43.775). WVE has higher annual earnings (EBITDA): -134.84M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. WVE (208M). SYRE has less debt than WVE: SYRE (0) vs WVE (21.7M). WVE has higher revenues than SYRE: WVE (93.9M) vs SYRE (0).
SYREWVESYRE / WVE
Capitalization1.82B1.16B156%
EBITDA-222.15M-134.84M165%
Gain YTD0.644-43.775-1%
P/E Ratio1.72N/A-
Revenue093.9M-
Total Cash527M208M253%
Total Debt021.7M-
FUNDAMENTALS RATINGS
SYRE vs WVE: Fundamental Ratings
SYRE
WVE
OUTLOOK RATING
1..100
8677
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
4064
P/E GROWTH RATING
1..100
77100
SEASONALITY SCORE
1..100
8532

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WVE's Valuation (50) in the Biotechnology industry is in the same range as SYRE (68) in the Pharmaceuticals Major industry. This means that WVE’s stock grew similarly to SYRE’s over the last 12 months.

WVE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that WVE’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as WVE (99) in the Biotechnology industry. This means that SYRE’s stock grew similarly to WVE’s over the last 12 months.

SYRE's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as WVE (64) in the Biotechnology industry. This means that SYRE’s stock grew similarly to WVE’s over the last 12 months.

SYRE's P/E Growth Rating (77) in the Pharmaceuticals Major industry is in the same range as WVE (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to WVE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYREWVE
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 18 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
SYRE
Daily Signal:
Gain/Loss:
WVE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPSRX25.520.17
+0.67%
NYLI Epoch Global Equity Yield Class R6
HLMIX30.930.15
+0.49%
Harding Loevner International Eq Instl
DCSYX68.880.05
+0.07%
Davis Balanced Fund Y
ACEAX10.90-0.02
-0.18%
AB All China Equity A
BREIX41.03-0.13
-0.31%
Baron Real Estate Institutional

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with APGE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.34%
APGE - SYRE
59%
Loosely correlated
+0.24%
CGON - SYRE
58%
Loosely correlated
+1.47%
IDYA - SYRE
57%
Loosely correlated
-0.19%
RGNX - SYRE
56%
Loosely correlated
+0.43%
NRIX - SYRE
56%
Loosely correlated
-5.37%
More

WVE and

Correlation & Price change

A.I.dvisor indicates that over the last year, WVE has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if WVE jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WVE
1D Price
Change %
WVE100%
-4.20%
XNCR - WVE
51%
Loosely correlated
-3.23%
SYRE - WVE
50%
Loosely correlated
+0.34%
NRIX - WVE
50%
Loosely correlated
-5.37%
NUVL - WVE
50%
Loosely correlated
+0.91%
XENE - WVE
49%
Loosely correlated
-0.60%
More